Antitumor activity of NVP-BKM120--a selective pan class I PI3 kinase inhibitor showed differential forms of cell death based on p53 status of glioma cells
about
PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastomaOther targeted drugs in melanomaTargeting the PI3K/Akt signaling pathway in gastric carcinoma: A reality for personalized medicine?New small molecules targeting apoptosis and cell viability in osteosarcomaDeconvolution of Buparlisib's mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention.Treatment with the PI3K inhibitor buparlisib (NVP-BKM120) suppresses the growth of established patient-derived GBM xenografts and prolongs survival in nude rats.Inhibition of phosphatidylinositol 3-kinase/AKT signaling by NVP-BKM120 promotes ABT-737-induced toxicity in a caspase-dependent manner through mitochondrial dysfunction and DNA damage response in established and primary cultured glioblastoma cells.Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical developmentBKM120 induces apoptosis and inhibits tumor growth in medulloblastomaPten loss in Olig2 expressing neural progenitor cells and oligodendrocytes leads to interneuron dysplasia and leukodystrophy.Coordinate activation of Shh and PI3K signaling in PTEN-deficient glioblastoma: new therapeutic opportunities.Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatmentCirculating tumor cells as a biomarker of response to treatment in patient-derived xenograft mouse models of pancreatic adenocarcinoma.Targeting class IA PI3K isoforms selectively impairs cell growth, survival, and migration in glioblastoma.Akt- or MEK-mediated mTOR inhibition suppresses Nf1 optic glioma growth.NVP-BKM120 potentiates apoptosis in tumor necrosis factor-related apoptosis-inducing ligand-resistant glioma cell lines via upregulation of Noxa and death receptor 5.The pan-class I phosphatidyl-inositol-3 kinase inhibitor NVP-BKM120 demonstrates anti-leukemic activity in acute myeloid leukemia.Protein phosphatase 2A and DNA-dependent protein kinase are involved in mediating rapamycin-induced Akt phosphorylation.Novel HSP90 inhibitor NVP-HSP990 targets cell-cycle regulators to ablate Olig2-positive glioma tumor-initiating cells.The PLK1 inhibitor GSK461364A is effective in poorly differentiated and anaplastic thyroid carcinoma cells, independent of the nature of their driver mutationsPI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma.Mutationally activated PIK3CA(H1047R) cooperates with BRAF(V600E) to promote lung cancer progression.Antitumor activity and induction of TP53-dependent apoptosis toward ovarian clear cell adenocarcinoma by the dual PI3K/mTOR inhibitor DS-7423.Hematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110α.Blockade efficacy of MEK/ERK-dependent autophagy enhances PI3K/Akt inhibitor NVP-BKM120's therapeutic effectiveness in lung cancer cellsPI3K and Akt as molecular targets for cancer therapy: current clinical outcomes.Current clinical development of PI3K pathway inhibitors in glioblastoma.Targeting the PI3K/AKT/mTOR signaling pathway in glioblastoma: novel therapeutic agents and advances in understanding.Dissecting the PI3K Signaling Axis in Pediatric Solid Tumors: Novel Targets for Clinical Integration.Targeting PI3K in Cancer: Any Good News?Targeting angiogenesis in renal cell carcinoma.The search for novel therapeutic strategies in the treatment of recurrent glioblastoma multiforme.Oncogenic nexus of cancerous inhibitor of protein phosphatase 2A (CIP2A): an oncoprotein with many hands.BKM-120 (Buparlisib): A Phosphatidyl-Inositol-3 Kinase Inhibitor with Anti-Invasive Properties in Glioblastoma.Mechanisms regulating glioma invasion.Buparlisib in breast cancer.PI3K inhibitor enhances the cytotoxic response to etoposide and cisplatin in a newly established neuroendocrine cervical carcinoma cell line.The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation.MSK1-Mediated β-Catenin Phosphorylation Confers Resistance to PI3K/mTOR Inhibitors in Glioblastoma.Genetic biomarkers of drug response for small-molecule therapeutics targeting the RTK/Ras/PI3K, p53 or Rb pathway in glioblastoma.
P2860
Q26766293-605344B5-A9D1-48C9-9A18-B5E14043C451Q26775594-556525BB-2ED2-4D92-B78C-A850486141B0Q26775940-B2318BC9-06A0-49F0-80B7-0B3FC1671A24Q28547760-4154A338-76E7-41FE-B25E-85E2C3C052EEQ30841629-ED5364E1-E3E9-42C6-87B4-1F2C196D1C73Q31106994-77C1BC3A-75DA-409D-BC97-79614F115858Q33750838-2858F9F2-17C8-4B34-974E-A825CF74A65BQ33776641-11B83C33-7F1A-4040-91E9-E629B50F0ABEQ33853264-ADFB29F8-94C0-4823-8621-B326676777A8Q33895438-7D2F6F08-AE66-4836-B92D-EE31B16734E8Q34374039-6985D2FF-CA7C-4D29-9700-9731B535B646Q34508976-429D4F9D-AD3D-482E-BBEF-E22C3AC5A41DQ35107404-38547B19-E95A-4C59-BD5A-F6E34A9A13E4Q35143738-72B291BF-57EF-438C-99A5-B25949BDBF4FQ35788976-BA761619-C19F-4075-A622-78D0A0FC2AE6Q35849961-5994FE9A-C0FD-4289-BFD6-C33A244267CBQ36379644-57F0B9D1-AF41-41E2-9DC1-E0DDB92A463CQ36832553-41ED840C-CF73-4290-883E-F8071B7BF6E0Q36847206-5F7A6632-C437-49FA-BDBE-CA465BEBFD41Q37199459-D106736B-3C85-4C9F-8158-77F0BF3BC790Q37252398-40C2580F-0A6E-4665-8DF1-CD55CD8325E3Q37301530-56072F28-0FD9-4A7D-B24D-877F5741B953Q37554263-1186181B-6C1E-4A17-A3BE-D7849CBA7393Q37679937-F890F817-83E1-4BEA-B0B0-CAA1DEDD4580Q37687154-639FD5B8-B18D-4FB9-8180-B225C1343DF2Q37727180-CBC64604-3F1A-4140-BEF4-52557555F08FQ38012438-F79A8D9B-BA93-48F6-AF3B-E61F49809E59Q38102636-9C4ACE29-A348-4DEE-AF20-22B1C554A94FQ38103561-3FC294FE-F38E-4333-A357-9E8F8165C7BEQ38105322-BEBCEAC5-3972-4DA0-9DA1-81A79D2E647CQ38132231-495A8EA7-338A-4D39-8007-333A7D2E4FA5Q38210665-60768101-E102-4BE4-812E-3414C6F0A1F7Q38228491-D31BC99D-BE3A-4AB7-BEF7-3DD3BB13FC3CQ38266139-E37A0EB3-4132-4DD4-80E8-317353100139Q38386429-E1A469D0-4C55-488C-B571-08A3971D0FFFQ38473709-5022C51E-8CEB-4757-B974-55DFFACAE1FEQ38704263-13D7A079-E1C5-414B-8D51-CDB292F4F084Q38766447-35A06ACA-310F-4C93-A9BE-E0FC320622B3Q38769933-E4D78BB8-DCFF-4B1B-9332-5797DE8D9E61Q38778367-AC5EC4E8-0964-45C3-89BD-D6071646082D
P2860
Antitumor activity of NVP-BKM120--a selective pan class I PI3 kinase inhibitor showed differential forms of cell death based on p53 status of glioma cells
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Antitumor activity of NVP-BKM1 ...... on p53 status of glioma cells
@en
Antitumor activity of NVP-BKM1 ...... on p53 status of glioma cells.
@nl
type
label
Antitumor activity of NVP-BKM1 ...... on p53 status of glioma cells
@en
Antitumor activity of NVP-BKM1 ...... on p53 status of glioma cells.
@nl
prefLabel
Antitumor activity of NVP-BKM1 ...... on p53 status of glioma cells
@en
Antitumor activity of NVP-BKM1 ...... on p53 status of glioma cells.
@nl
P2093
P2860
P1476
Antitumor activity of NVP-BKM1 ...... on p53 status of glioma cells
@en
P2093
Carlos Garcia-Echevrria
Deepti Ramnarian
Dimpy Koul
Juinn-Lin Liu
Ningyi Tiao
Ruijun Shen
Sauveur-Michel Maira
Shuzhen Wang
Tiffany A LaFortune
P2860
P304
P356
10.1158/1078-0432.CCR-11-1558
P407
P577
2011-11-07T00:00:00Z